ViroCyt white paper: Exhibitors of the World Vaccine Congress, Washington, 2015

Guest blog: ViroCyt ‘Virotherapy Process Optimization’ white paper

An emerging application of viruses involves engineering them to treat diseases using a number of approaches. Broadly defined under the “Virotherapy” umbrella, these include viral vectors used for gene therapy, oncolytic viruses and viral immunotherapy. A significant challenge, as it is for any virus-based technology, is gaining a clear picture of the quality of a sample at any given point: …

Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …

Top 10 Equipment Manufacturers (EQMs)

Top 10 Equipment Manufacturers (EQMs)

This eBook features a detailed synopsis of the top 10 equipment manufacturers (EQMs), for all stages of vaccine development; from the early stages right through to the drug being made available to the market. Tailor-made to assist you in choosing the right EQM partner, specific to your development needs, the aim is to help condense down the lengthy process of …

vaccine manufacturers

Top 3 Sparks of Interest for Leading Vaccine Academics

Recently we undertook the research for the 15th annual World Vaccine Congress. As part of that research, we spoke to leading vaccine academics from the likes of University of Oxford and Erasmus MC to find out what they thought were the most interesting trends in industry at the moment. These were the top 3: 1. The renaissance of veterinary vaccines …

Vaccine Asia Live: NIAID’s Effort on Dengue Vaccine R&D

Addressing Asia’s needs for vaccines in dengue, Dr Zou Lanling, Bacteriology Program Officer & Chief of Translational Sciences Section of National Institutes of Health USA, shared the efforts put into dengue vaccine R&D by National Institute of Allergy and Infectious Diseases(NIAID). NIAID conducts and supports research to develop vaccines, therapeutics and diagnostics to help understand, treat, and prevent infectious, immunologic, …

Vaccine

Vaccine Asia Live: Novel Vaccines for Emerging Diseases

Most vaccines developed target infectious diseases and cancer, with cancer vaccines being listed more under therapeutic vaccines. To enlighten us on vaccines for infectious diseases, Ms Zhang Xiaoshu, Director of Business Development at BravoBio, China, presented on the topic of Novel Vaccines for Emerging Diseases. BravoBio was founded in 2011 with its  headquarters in Shanghai and multiple sites in China. …

Vaccine Asia Live: Recombinant Lipoimmunogen-based therapeutic HPV Vaccine

Human Papilloma Virus(HPV) is a DNA virus that can cause skin & genital warts as well as cervical and osopharyngeal cancers. In the US, there is an increasing trend in cervical cancer in women and osopharyngeal cancer in men.  To make things worse, there are no treatments available for HPV infection. Thus, HPV vaccines have become the most common mode …

Vaccine Asia Live: Forging Strategic Partnership for R&D to Meet High Demands for Vaccines in Asia

As a unique feature of Terrapinn conferences, the roundtable discussions serve as an interactive platform for meaningful discussion. At World Vaccine Congress Asia 2014, Do Tuan Dat, President & General Director of Vabiotech, Vietnam, moderated the discussion on the topic of “Forging Strategic Partnership for R&D to Meet High Demands for Vaccines in Asia”. A consensus was reached among the …

Round up from the World Vaccine Congress 2014

  So the World Vaccine Congress is over for its 14th year! With 80+ speakers, 40+ sponsors and over 60 sessions of scientific, corporate development and future-looking content, it was a busy few days! Opening with Dr Gregory Poland from the Mayo Clinic talking about the future of vaccinology, right from the start the focus was on what will be …

Presentation: Vaccine development formulation with adjuvants

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Emanuele Montomoli from the Lab. of Molecular Epidemiology, University of Siena entitled: ‘Vaccine development …